D
irect oral anticoagulants (DOACs) are recommended by international guidelines and meanwhile established in primary and secondary prevention of cardioembolic ischemic stroke in nonvalvular atrial fibrillation. [1] [2] [3] While no routine coagulation monitoring is required in patients taking DOAC, measurement of specific DOAC plasma levels might be useful for the management of emergencies including ischemic stroke occurring during treatment with DOAC. 4 In patients on vitamin K antagonists (VKAs) the clinical course and the severity of stroke as well as the functional outcome depend on the quality of anticoagulation at onset, reflected by the international normalized ratio (INR) measured at the time of hospital admission. 5, 6 Different mechanisms might be responsible for this clinical benefit, including a higher rate of spontaneous vessel recanalization, improved cerebral microcirculation and lower rates of early stroke recurrence or thrombotic complications. [7] [8] [9] Because of the markedly different pharmacokinetic and pharmacodynamic profiles of DOAC and VKA, it is unknown, if a similar association between preexisting anticoagulation and stroke severity also applies to patients on DOAC. In the present study, we investigated the influence of DOAC plasma levels on stroke severity, occurrence of large vessel occlusion (LVO) and functional outcome in patients suffering from acute cerebral ischemia occurring during DOAC therapy.
Neurovascular and Laboratory Diagnostics
The diagnosis of ischemic stroke was established on clinical examination by an experienced stroke neurologist and cerebral imaging. All patients received a thorough neurovascular assessment by ultrasound studies of the extracranial and intracranial cerebral vessels. In addition, computed tomographic or magnetic resonance imaging angiography was performed in all patients who appeared clinically eligible for acute recanalization therapy (intravenous thrombolysis or endovascular therapy) on admission. In patients on treatment with VKA, the activity of anticoagulation was assessed using the INR on admission and categorized according to a threshold set at 1.7. In patients on DOAC therapy on admission, specific plasma levels were assessed. Measurements for rivaroxaban, apixaban, and edoxaban were performed using anti-Xabased chromogenic assays (STA-Liquid Anti-Xa, Diagnostica STAGO S.A.S., France) with anticoagulant-specific calibration (Diagnostica STAGO S.A.S., France). Dabigatran plasma level was determined using the Hemoclot direct thrombin inhibitor assay (HYPHEN BioMed, France). The activity was categorized into low (<50 ng/mL), intermediate (50-100 ng/mL), or high (>100 ng/mL), according to our institutional treatment algorithm for patients with acute cerebral ischemia on DOAC therapy: plasma level <50 ng/mL: supportive for intravenous thrombolysis with recombinant tissue-type plasminogen activator (rtPA); 50 to 100 ng/mL: intravenous thrombolysis with recombinant tissue-type plasminogen activator (rtPA) after individual consideration; >100 ng/mL: recombinant tissue-type plasminogen activator (rtPA) excluded; endovascular therapy is performed independently from plasma levels in patients with LVO. The same thresholds were used for the thrombin inhibitor dabigatran and the factor Xa inhibitors rivaroxaban, apixaban, and edoxaban.
Functional Outcome Assessment
Functional outcome was assessed via telephone interview on day 90 using the modified Rankin Scale (mRS). Patients lost to follow-up were excluded from outcome analysis. Baseline characteristics and therapy in patients on DOAC with 90-day follow-up versus patients lost to follow-up are given with Table I in the online-only Data Supplement.
Study Objectives
The primary objective of the study was the association of DOAC plasma levels on admission and stroke severity (National Institutes of Health Stroke Scale [NIHSS] score on admission, persisting neurological deficits, or visibility of infarction on imaging as well as the presence of LVO on admission). Acute occlusion of internal carotid artery, anterior cerebral artery, middle cerebral artery, posterior cerebral artery, vertebral artery, or basilar artery was defined as acute LVO. The secondary objective was the functional outcome at day 90 measured on the mRS. Favorable outcome was defined as pre-mRS or mRS score of ≤2.
Statistical Analyses
Statistical comparison between patient-groups was performed using Kruskal-Wallis, Mann-Whitney U, the χ 2 test, and Fisher exact test, as appropriate. Statistical significance was set a priori at P values <0.05. Associations are presented as odds ratios (OR) with corresponding 95% CI. Variables associated with occurrence of LVO in the initial univariable analyses at P values <0.1 were included in the multivariable model as candidate variables. Multivariable analysis was performed separately for low and high plasma levels (DOAC) or INR<1.7 and INR≥1.7 (VKA). Statistical significance in the multivariable analyses was set at P values <0.05. E values were calculated to assess the potential contribution of unmeasured confounding.
(Material in the online-only Data Supplement) Receiver operating characteristics analyses were conducted to investigate the association of DOAC plasma levels (DOAC patients) or INR (VKA patients) with the occurrence of LVO or NIHSS score of ≥10. The best cutoff points for discriminating LVO and NIHSS score of ≥10 were identified by the Youden index. Statistical analyses were performed using IBM SPSS Statistics 21 software package (SPSS Inc, Chicago, IL).
Standard Protocol Approval
The study was approved by the ethics committee of the Faculty of Medicine, University of Erlangen-Nuremberg, Germany. Written informed patient consent was not required according to the ethics committee decision.
Results
Four hundred sixty patients with acute cerebral ischemia while on oral anticoagulation because of atrial fibrillation were included. Two hundred thirty-four patients (50.9%) were on DOAC therapy and 226 patients (49.1%) used VKA. DOAC plasma levels were available in 177 patients (75.6%), among them 61 (34.5%) used rivaroxaban, 24 (13.6%) dabigatran, 89 (50.3%) apixaban, and 3 (1.7%) edoxaban. Characteristics of patients without plasma levels available were similar except for the score on the NIHSS on admission (Table II in the online-only Data Supplement). Functional plasma levels were found to be low (<50 ng/mL) in 49 (27.7%), intermediate (50-100 ng/mL) in 41 (23.2%), and high (>100 ng/mL) in 87 patients (49.2%). Plasma level groups were similar for relevant demographic parameters ( Table 1 ; Figures 1 and 2 .) Receiver operating characteristic analysis revealed a strong, negative association between DOAC plasma level and severe stroke (NIHSS score of ≥10; area under the curve =0.651 [95% CI, 0.555-0.747]; P=0.002) with the best discrimination for prediction of severe stroke at a threshold of 58 ng/mL (Youden index 0.288; Table 2 ).
The neurovascular status was examined in all patients by ultrasound studies, computed tomographic or magnetic resonance imaging angiography was additionally acquired in 88 of 177 patients on DOAC therapy (49.7%). Acute LVO on admission was diagnosed in 45 of 177 patients (25.4%, occlusion of internal carotid artery n=9, middle cerebral artery n=26, posterior cerebral artery n=3, vertebral artery n=1, and basilar artery n=6 
Discussion
There are 3 major findings from this cohort study: (1) The majority of ischemic strokes occurred despite measurable antithrombotic activity on admission; (2) In analogy to VKA therapy, stroke severity and occurrence of LVO in patients on DOAC therapy are associated with the level of anticoagulant activity on admission; and (3) Low antithrombotic activity is an independent predictor of vessel occlusion, while high plasma levels seem to be protective.
A positive effect of sufficient anticoagulation at stroke onset on stroke severity and outcome could repeatedly be demonstrated for patients on VKA therapy in several studies. 5, 6 Data from our cohort reconfirm these findings. Recently, this positive effect was also reported in a study including patients on assumed DOAC therapy, whereas an INR≥2 (OR 0.23 [95% CI, 0.10-0.53]) or DOAC intake (OR 0.48 [95% CI, 0.27-0.86]) were associated with a lower probability of severe stroke (NIHSS score of ≥ 11 on admission) after adjustment for confounders. 11 However, the results from this study were limited by the fact that no direct evidence of anticoagulant activity in DOAC patients was available because of missing plasma level measurements.
No routine coagulation monitoring is required for patients on DOAC. However, the measurement of DOAC plasma levels can guide the management of emergency situations such as ischemic stroke in patients on DOAC therapy as it allows the identifications of patients with low antithrombotic activity, who are potentially eligible for intravenous rtPA use. 4 Consequently, measurement of functional plasma levels is increasingly common in high-volume neurovascular centers for selection of potential recanalization therapies. [12] [13] [14] [15] However, up to date no generally accepted values representing low, intermediate, and high activity of anticoagulation The best DOAC plasma level cutoff point was identified by the Youden index. DOAC indicates direct oral anticoagulant; LVO, large vessel occlusion; and NIHSS, National Institutes of Health Stroke Scale. exist. The values in this study were chosen for an institutional algorithm as a result of an interdisciplinary decision making process among clinicians and haemostaseologists. This process was guided by preclinical data, results from the randomized trials and results from smaller cohort studies. 12, 13, [16] [17] [18] Correlation between low plasma concentrations of dabigatran and edoxaban and higher incidence of ischemic stroke Low DOAC plasma level: <50 ng/mL; Intermediate DOAC plasma level: 50-100 ng/mL; High DOAC plasma level: >100 ng/mL; and Normal renal function defined as glomerular filtration rate >60 mL/min per 1.73 m2. DOAC indicates direct oral anticoagulant; IQR, interquartile range; LVO, large vessel occlusion; NIHSS, National Institutes of Health Stroke Scale; and pre-mRS, pre-modified Rankin Scale. Favorable outcome defined as pre-mRS or mRS score of ≤2 at day 90.
*Data missing in 1 patient. †n=100/36. ‡Time from symptom onset to admission. 17, 18 In a case series including 19 patients admitted for acute stroke to our tertiary university stroke center while on dabigatran therapy higher dabigatran plasma levels were measured in 4 patients with intracerebral hemorrhage compared with 15 patients with ischemic stroke. 19 Baseline characteristics were similar in patients with LVO and without LVO except for younger age (median 77.0 [72. .0] versus 81.0 [77.0-86.0]; P=0.003) and better renal function (68.9% versus 49.2%; P=0.023) in LVO patients. DOACs are mainly eliminated via the kidney and it is necessary to adjust the dose in patients with impaired renal function. However, in our study, no significant association between low plasma levels and patients using the low DOAC doses was found. Nevertheless, lower plasma levels and limited efficacy of DOAC were reported in patients with good renal function (glomerular filtration rate>95 mL/min) and glomerular hyperfiltration. 20, 21 Lower plasma levels and higher proportion of patients with normal renal function found in LVO patients in our study could substantiate this observation.
This study has relevant limitations: Patients without plasma levels available (24.4%) had lower NIHSS scores on admission and were excluded from the analysis. Therefore, a potential selection bias cannot be excluded. The primary objective was the stroke severity on hospital admission and the presence of LVO, while analyses on the mRS after 90 days were certainly underpowered. Future research should further explore the impact of DOAC plasma levels on functional end points and adjust for relevant confounding factors including intravenous thrombolysis and thrombectomy. The study focused on patients with reported use of DOAC within 48 hours before admission. However, it is unknown to what extend low plasma levels were caused by incompliance, forgotten DOAC intake or the inappropriateness of the DOAC dose regimens before admission.
Conclusions
The level of anticoagulant activity in patients with acute cerebral ischemia is associated with stroke severity and the occurrence of LVO. This applies to both, patients on VKA and DOAC.
